Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aldeyra Therapeutics, Inc. (ALDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/29/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics, Inc. Presentation",
"Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis Pigmentosa"
05/04/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights"
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma"
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease"
12/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Second Amendment to Loan and Security Agreement, and effective as of December 31, 2022, by and among Aldeyra Therapeutics, Inc., Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital, Inc"
12/21/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/29/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Scheduled for the Fourth Quarter of 2022 Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected in the Third or Fourth Quarter of 2022 Results from the Phase 2 Clinical Trial of ADX-2191 in Retinitis Pigmentosa Expected in the First Half of 2023 Results from the Phase 3 INVIGORATE-2 Trial of Reproxalap in Allergic Conjunctivitis Expected in 2023"
08/05/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/28/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aldeyra Therapeutics Announces Chief Financial Officer Transition"
03/29/2022 8-K Investor presentation
Docs: "Slide Presentation of Aldeyra Therapeutics, Inc.",
"Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day"
03/17/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights"
12/21/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics, Inc. Presentation",
"Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease"
11/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application Submission Guidance"
11/02/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double- Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease"
10/28/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aldeyra Therapeutics Reports Third-Quarter 2021 Financial Results and Recent Corporate Highlights"
08/05/2021 8-K Quarterly results
06/09/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/27/2021 8-K Quarterly results
04/21/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy